Zoran Zdraveski
Conseiller Juridique Général chez TSCAN THERAPEUTICS, INC.
Fortune : 2 M $ au 31/05/2024
Postes actifs de Zoran Zdraveski
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| TSCAN THERAPEUTICS, INC. | Conseiller Juridique Général | 09/09/2021 | - |
| Secrétaire Général | 09/09/2021 | - |
Historique de carrière de Zoran Zdraveski
Anciens postes connus de Zoran Zdraveski
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| MAGENTA THERAPEUTICS | Conseiller Juridique Général | 01/04/2017 | 01/04/2021 |
| Secrétaire Général | 01/03/2018 | 01/04/2021 | |
| EPIZYME, INC. | Corporate Officer/Principal | 01/07/2012 | 01/04/2017 |
Formation de Zoran Zdraveski
| Massachusetts Institute of Technology | Doctorate Degree |
| Suffolk University Law School | Graduate Degree |
| Southern Methodist University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| General Counsel | 2 |
| Corporate Secretary | 2 |
| Corporate Officer/Principal | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| TSCAN THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Zoran Zdraveski
- Expérience
